ArticleKidney medicine2025
The Uptake of Influenza, Pneumococcal, Shingles, and COVID-19 Vaccines Among US Adults With and Without Kidney Disease: Findings From the Behavioral Risk Factor Surveillance System 2018-2022.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Persons with kidney disease are at risk of infections such as influenza, pneumonia, shingles, and coronavirus-2019 (COVID-19), which can be prevented by vaccination. However, comparative uptake across these vaccines in people with and without kidney disease has not been well described. Study Design: A cross-sectional analysis. Setting & Participants: Vaccine-eligible adults in the Behavioral Risk Factor Surveillance System (BRFSS) 2018-2022. Exposures: Self-reported status of kidney disease. Outcomes: The uptake of the influenza (past 12 months), pneumococcal (lifetime), shingles (lifetime), and COVID-19 (at least one dose) vaccines. Analytical Approach: Multivariable logistic regressions to compare the odds of vaccine uptake between those with and without kidney disease. The results were pooled to show the overall uptake from 2018 to 2022, except for the COVID-19 vaccine, for which data were only available for 2022. Results: In the pooled sample of BRFSS 2018-2022, 4.0% had kidney disease. In people with kidney disease, the highest uptake was observed for COVID-19 (87.0%), followed by pneumococcal (63.6%), influenza (59.6%), and shingles (37.1%) vaccines. These numbers were higher compared with those without kidney disease (78.4% for COVID-19, 52.9% for pneumococcal, 41.8% for influenza, and 31.1% for shingles vaccines), but the differences varied by vaccine type. In multivariable logistic models, the largest odds ratio in uptake of those with versus without kidney disease was observed for pneumococcal vaccine (aOR, 1.58 [95%CI, 1.48-1.69]), followed by COVID-19 (1.50 [1.18-1.89]), influenza (1.35 [1.28-1.43]), and shingles (1.03 [0.91-1.17]) vaccines. These findings were consistent across age and race/ethnicity groups, with lower uptakes generally in younger (vs older) and non-Hispanic African American and Hispanic (vs non-Hispanic White) participants. Limitations: Possible misclassification of kidney disease status due to self-report. Conclusions: Vaccine uptakes in people with kidney disease varied by vaccine type and remained suboptimal, particularly for shingles vaccine. Efforts are needed to increase vaccine uptake and ensure all recommended vaccines are offered to people with kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.